SLShengpeng Liu

Shengpeng Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shengpeng Liu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Oxidative stress as a bridge between age and stroke: A narrative review

    by Shengjie Feng, Miaoxian Yang, Shengpeng Liu, Yu He, Shuixiang Deng, Ye Gong


  • Open Access

    Secukinumab Attenuates Neuroinflammation and Neurobehavior Defect via PKCβ /ERK/NF-κB Pathway in a Rat Model of GMH

    by Shengpeng Liu, Shuixiang Deng, Yan Ding, Jerry J. Flores, Xiaoli Zhang, Xiaojing Jia, Xiao Hu, Jun Peng, Gang Zuo, John H. Zhang, et al.

    AimsGerminal matrix hemorrhage (GMH) is a disastrous clinical event for newborns. Neuroinflammation plays an important role in the development of neurological deficits after GMH. The purpose of this study is to investigate the anti-inflammatory role of secukinumab after GMH and its underlying mechanisms involving PKCβ/ERK/NF-κB signaling pathway.MethodsA total of 154 Sprague-Dawley P7 rat pups were used. GMH was induced by intraparenchymal injection of bacterial collagenase. Secukinumab was administered intranasally post-GMH. PKCβ activator PMA and p-ERK activator Ceramide C6 were administered intracerebroventricularly at 24h prior to GMH induction, respectively. Neurobehavioral tests, Western blot and immunohistochemistry were used to evaluate the efficacy of secukinumab in both short-term and long-term studies.ResultsEndogenous IL-17A, IL-17RA, PKCβ and p-ERK were increased after GMH. Secukinumab treatment improved short- and long-term neurological outcomes, reduced the expression of MPO and Iba-1 in the perihematoma area, and inhibited the expression of proinflammatory factors, such as NF-κB, IL-1β, TNF-α and IL-6. Additionally, PMA and ceramide C6 abolished the beneficial effects of secukinumab. ConclusionSecukinumab treatment suppressed neuroinflammation and attenuated neurological deficits after GMH, which was mediated through the downregulation of the PKCβ/ERK/NF-κB pathway. Secukinumab treatment may provide a promising therapeutic strategy for GMH patients.


  • Open Access

    IL‐20R Activation via rIL‐19 Enhances Hematoma Resolution through the IL‐20R1/ERK/Nrf2 Pathway in an Experimental GMH Rat Pup Model

    by Shengpeng Liu, Jerry J. Flores, Bo Li, Shuixiang Deng, Gang Zuo, Jun Peng, Jiping Tang, John H. Zhang

    Aims. Blood clots play the primary role in neurological deficits after germinal matrix hemorrhage (GMH). Previous studies have shown a beneficial effect in blood clot clearance after hemorrhagic stroke. The purpose of this study is to investigate interleukin‐19’s role in hematoma clearance after GMH and its underlying mechanism of IL‐20R1/ERK/Nrf2 signaling pathway. Methods. A total of 240 Sprague‐Dawley P7 rat pups were used. GMH was induced by intraparenchymal injection of bacterial collagenase. rIL‐19 was administered intranasally 1 hour post‐GMH. IL‐20R1 CRISPR was administered intracerebroventricularly, or Nrf2 antagonist ML385 was administered intraperitoneally 48 hours and 1 hour before GMH induction, respectively. Neurobehavior, Western blot, immunohistochemistry, histology, and hemoglobin assay were used to evaluate treatment regiments in the short‐ and long‐term. Results. Endogenous IL‐19, IL‐20R1, IL‐20R2, and scavenger receptor CD163 were increased after GMH. rIL‐19 treatment improved neurological deficits, reduced hematoma volume and hemoglobin content, reduced ventriculomegaly, and attenuated cortical thickness loss. Additionally, treatment increased ERK, Nrf2, and CD163 expression, whereas IL‐20R1 CRISPR‐knockdown plasmid and ML385 inhibited the effects of rIL‐19 on CD163 expression. Conclusion. rIL‐19 treatment improved hematoma clearance and attenuated neurological deficits induced by GMH, which was mediated through the upregulation of the IL‐20R1/ERK/Nrf2 pathways. rIL‐19 treatment may provide a promising therapeutic strategy for the GMH patient population.